A new theranostics pairing tested in breast cancer patients – NCI Center for Cancer Research
NCI Center for Cancer Research shared on LinkedIn:
“A Target of Opportunity: Peter L. Choyke, Chief of the Molecular Imaging Branch (left) and Frank I. Lin, Lasker Clinical Research Scholar in the Molecular Imaging Branch, wrote a joint commentary on a new theranostics pairing tested in breast cancer patients that shows therapeutic promise.
‘The study draws attention to the expression of SSTR2 in breast cancer, especially in ER-positive tumors and demonstrates that SSTR2-targeted imaging can help guide decisions to use SSTR2 radioligand therapy … it shows that α-based Ac-225 DOTATATE, although not yet approved by the U.S. Food and Drug Administration, has potential for dramatic responses in at least some selected patients. The results will hopefully encourage clinician-scientists who treat metastatic breast cancer to consider studying SSTR2-targeted therapies in prospective clinical trials.”
Authors and Editors: Gary A. Ulaner, Louis A. VanderMolen, Gary Li, Denis Ferreira, Linda Moy and Sarah Atzen.
Somatostatin Radioligand Therapy of Breast Cancer: A Target of Opportunity
Authors: Frank Lin and Peter L. Choyke.
